Flexible, clinically adaptable, non-viral approaches to CAR TCR methodologies

August 04, 2020 11:00 AM EDT

Rama S Shivakumar
Research Scientist and Customer Application Specialist, MaxCyte Inc.

ABSTRACT
In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies that demonstrate the successful use of MaxCyte’s clinically validated, scalable electroporation system in the pre-clinical and clinical scale engineering of resting and activated T cells using a mesothelin specific CARmRNA; in the enhancement of NK cell cytotoxicities against B cell malignancies using an antiCD19 CAR mRNA; in the transposon (Piggybac and Sleeping Beauty) based gene delivery for manufacture of CAR-T cells ; and finally in the gene editing of T cells for improving the efficacy of a TCR immunotherapy. In particular, during this webinar she will discuss how MaxCyte’s versatile ExPERT platform can enable the next-generation non-viral CAR T therapies including allogeneic, off-the-shelf modalities with the potential for enhanced effectiveness for refractory cancer.

REGISTER NOW

Scalable Manufacturing and Nanovesicle Delivery of CRISPR-Cas9 Ribonucleoproteins Using a cGMP- Compliant Cell Engineering Platform

September 17, 2020 8:00 AM PT

Peter Gee
Field Application Scientist
MaxCyte Inc.

ABSTRACT
CRISPR-Cas9 has tremendous potential as a therapeutic tool for treating human diseases. However, prolonged expression of the nuclease and gRNA from viral vectors in an in vivo context may cause unwanted off-target activity and immunogenicity. To overcome these safety issues, a system was recently developed for transient delivery of CRISPR-Cas9 ribonucleoprotein (RNP), recruiting Cas9 protein by chemically-induced dimerization and sgRNA via a viral RNA packaging signal into extracellular nanovesicles.  This system, termed NanoMEDIC (nanomembrane-derived extracellular vesicles for the delivery of macromolecular cargo), demonstrates efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells and myoblasts, and also in vivo in a luciferase reporter mouse model.

REGISTER NOW

Upcoming webinars

SEPT 2020

OCT 2020

NOV 2020

JAN 2021

ENJOYED OUR WEBINARS?

DOWNLOAD THEM HERE AFTER THE 4TH, 2020

Contact

Find out how the ExPERT platform can help accelerate your research needs!